Immunomodulation and therapeutic characterization of thymosin fraction five

James E Talmadge, Keith A. Uithoven, Barbara F. Lenz, Michael Chirigos

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In this report we describe the characterization of the immunomodulatory efficiency and therapeutic properties of thymosin fraction five (F5). We consistently observed the immunostimulation of T-cell activity in assays of allogeneic mixed lymphocyte response (MLR) and the development of cytotoxic effector cells in an allogeneic mixed lymphocyte tumor response-cell-mediated cytotoxicity assay (MLTR-CMC). No induction of suppressor cell activity was observed. Thymosin F5 also acted successfully as an adjuvant when admixed with irradiated tumor cells. We were unable to demonstrate either NK cell or macrophage activation by thymosin F5. Therapeutic protocols using thymosin F5 and directed against pre-existing experimental and spontaneous metastases, had a significant immunotherapeutic potential.

Original languageEnglish (US)
Pages (from-to)185-194
Number of pages10
JournalCancer Immunology Immunotherapy
Volume18
Issue number3
DOIs
StatePublished - Dec 1 1984

Fingerprint

Thymosin
Immunomodulation
Lymphocytes
Macrophage Activation
Therapeutics
Natural Killer Cells
Immunization
Neoplasms
Neoplasm Metastasis
T-Lymphocytes

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

Immunomodulation and therapeutic characterization of thymosin fraction five. / Talmadge, James E; Uithoven, Keith A.; Lenz, Barbara F.; Chirigos, Michael.

In: Cancer Immunology Immunotherapy, Vol. 18, No. 3, 01.12.1984, p. 185-194.

Research output: Contribution to journalArticle

Talmadge, James E ; Uithoven, Keith A. ; Lenz, Barbara F. ; Chirigos, Michael. / Immunomodulation and therapeutic characterization of thymosin fraction five. In: Cancer Immunology Immunotherapy. 1984 ; Vol. 18, No. 3. pp. 185-194.
@article{23d37415818a4bf9b2a342a809282dce,
title = "Immunomodulation and therapeutic characterization of thymosin fraction five",
abstract = "In this report we describe the characterization of the immunomodulatory efficiency and therapeutic properties of thymosin fraction five (F5). We consistently observed the immunostimulation of T-cell activity in assays of allogeneic mixed lymphocyte response (MLR) and the development of cytotoxic effector cells in an allogeneic mixed lymphocyte tumor response-cell-mediated cytotoxicity assay (MLTR-CMC). No induction of suppressor cell activity was observed. Thymosin F5 also acted successfully as an adjuvant when admixed with irradiated tumor cells. We were unable to demonstrate either NK cell or macrophage activation by thymosin F5. Therapeutic protocols using thymosin F5 and directed against pre-existing experimental and spontaneous metastases, had a significant immunotherapeutic potential.",
author = "Talmadge, {James E} and Uithoven, {Keith A.} and Lenz, {Barbara F.} and Michael Chirigos",
year = "1984",
month = "12",
day = "1",
doi = "10.1007/BF00205510",
language = "English (US)",
volume = "18",
pages = "185--194",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "3",

}

TY - JOUR

T1 - Immunomodulation and therapeutic characterization of thymosin fraction five

AU - Talmadge, James E

AU - Uithoven, Keith A.

AU - Lenz, Barbara F.

AU - Chirigos, Michael

PY - 1984/12/1

Y1 - 1984/12/1

N2 - In this report we describe the characterization of the immunomodulatory efficiency and therapeutic properties of thymosin fraction five (F5). We consistently observed the immunostimulation of T-cell activity in assays of allogeneic mixed lymphocyte response (MLR) and the development of cytotoxic effector cells in an allogeneic mixed lymphocyte tumor response-cell-mediated cytotoxicity assay (MLTR-CMC). No induction of suppressor cell activity was observed. Thymosin F5 also acted successfully as an adjuvant when admixed with irradiated tumor cells. We were unable to demonstrate either NK cell or macrophage activation by thymosin F5. Therapeutic protocols using thymosin F5 and directed against pre-existing experimental and spontaneous metastases, had a significant immunotherapeutic potential.

AB - In this report we describe the characterization of the immunomodulatory efficiency and therapeutic properties of thymosin fraction five (F5). We consistently observed the immunostimulation of T-cell activity in assays of allogeneic mixed lymphocyte response (MLR) and the development of cytotoxic effector cells in an allogeneic mixed lymphocyte tumor response-cell-mediated cytotoxicity assay (MLTR-CMC). No induction of suppressor cell activity was observed. Thymosin F5 also acted successfully as an adjuvant when admixed with irradiated tumor cells. We were unable to demonstrate either NK cell or macrophage activation by thymosin F5. Therapeutic protocols using thymosin F5 and directed against pre-existing experimental and spontaneous metastases, had a significant immunotherapeutic potential.

UR - http://www.scopus.com/inward/record.url?scp=0021681966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021681966&partnerID=8YFLogxK

U2 - 10.1007/BF00205510

DO - 10.1007/BF00205510

M3 - Article

VL - 18

SP - 185

EP - 194

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 3

ER -